Hybrid polypeptides with enhanced pharmacokinetic properties

Details Hybrid polypeptides with enhanced pharmacokinetic properties Hybrid polypeptides with enhanced pharmacokinetic properties

A - Human Necessities

61

K

A61K 38/02 (2006.01) A61K 38/08 (2006.01) A61K 38/10 (2006.01) A61K 38/16 (2006.01) A61K 38/18 (2006.01) A61K 38/19 (2006.01) A61K 38/22 (2006.01) C07K 5/117 (2006.01) C07K 7/06 (2006.01) C07K 7/08 (2006.01) C07K 14/00 (2006.01) C07K 14/16 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2377677

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

La présente invention concerne des séquences peptidiques activatrices issues à l'origine de diverses séquences protéiques d'une enveloppe rétrovirale (gp41) qui améliorent les propriétés pharmacocinétiques de tout polypeptide noyau auquel elles sont liées. L'invention repose sur le fait que des polypeptides hybrides comprenant les séquences peptidiques activatrices liées à un polypeptide noyau possèdent des propriétés pharmacocinétiques améliorées, telles qu'une demi-vie biologique prolongée. L'invention concerne outre des procédés destinés à améliorer les propriétés pharmacocinétiques de tout polypeptide noyau par liaison des séquences peptidiques activatrices à ce dernier. Les polypeptides noyaux de l'invention peuvent comprendre tout peptide présentant une utilité pharmacologique et pouvant être utilisé, par exemple, comme réactif thérapeutique ou prophylactique.

Affiliated with

Also associated with

Rating

Hybrid polypeptides with enhanced pharmacokinetic properties does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybrid polypeptides with enhanced pharmacokinetic properties, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid polypeptides with enhanced pharmacokinetic properties will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1866579